ISSN:
1437-7780
Keywords:
DU6859a
;
injectable drug
;
antibacterial activity
;
efficacy
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract DU6859a was evaluated for its in vitro and in vivo antibacterial activities in comparison with those of imipenem, meropenem, cefpirome, vancomycin, gentamicin, ciprofloxacin and levofloxacin. DU6859a had activity comparable to that of imipenem against methicillin-susceptible staphylococci and penicillin-susceptible and-resistantStreptococcus pneumoniae, with MICs at which 90% of strains tested are inhibited (MIC90)≤0.063μg/mL. Against methicillin-resistant staphylococci and enterococci, DU6859a was as active as vancomycin and more active than other drugs tested, with MIC90s ranging from 1 to 4 μg/mL. DU6859a was as active as ciprofloxacin and more active than other drugs tested against imipenem-resistantPseudomonas aeruginosa. Differences in activity between DU6859a and reference drugs against ciprofloxacin-resistant and gentamicin-resistantP. aeruginosa were particularly striking. The in vivo efficacy of subcutaneous injections of DU6859a against experimental septicemia, respiratory and pyelonephritic infections caused by gram-positive and-negative bacteria, including methicillin-resistantStaphylococcus aureus and imipenem-resistantP. aeruginosa, reflected its potent in vitro activity.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF02351567
Permalink
